Listen to Valeant's wording.
"We believe that oncology has similar characteristics to our current therapeutic portfolios, such as strong growth, high durability, strong patient and physician loyalty, and a terrific reimbursement regime," stated J. Michael Pearson, chairman and chief executive officer. "We have not previously found an economic way to enter this market, but with the unique dynamics of this situation, we believe that this transaction will create significant shareholder value."
They don't stand a chance. Other BP's with cash will pour boiling oil on them. Valeant has 50b market cap, 800 million cash and 15 billion in debt. Compared to company's like Pfizer with 35 billion cash, Gsk 6 billion cash, Gild 10 billion cash and Bmy at 7 billion cash. These guys will crush Valeant.
3x revenue bid around a billion should start thinning out the bids but it its a auction so its anyone's guess.
